Repository logo
 
Publication

Valor prognóstico da expressão por imuno-histoquímica do c-erb-2: em doentes sob terapêutica adjuvante com Tamoxifeno por carcinoma primário da mama

dc.contributor.authorAntunes, A
dc.contributor.authorSilva, T
dc.contributor.authorGodinho, I
dc.contributor.authorAmaral, A
dc.contributor.authorOliveira, CF
dc.date.accessioned2008-11-18T11:46:57Z
dc.date.available2008-11-18T11:46:57Z
dc.date.issued2004
dc.description.abstractINTRODUCTION: The c-erb2 proto-oncogene is a member of the epidermal growth factor receptor family and has been associated with a more aggressive breast tumour biology and resistance to some types of treatments. AIMS: To evaluate the prognostic value of c-erb-2 receptor, from primary breast cancer on tamoxifen therapy. METHODS: We examined 66 paraffin-embedded sections from primary breast cancers. Patients were treated with surgery plus adjuvant treatment with tamoxifen; 58% had also received chemotherapy and/or radiotherapy. Membrane staining for c-erb-2 was evaluated by immunohistochemistry and overall survival and relapse-free survival were compared between positives and negatives for c-erb-2. RESULTS: 43,9% of tumours over expressed c-erb-2 receptor, but this was not associated with a worse prognosis on overall survival either on relapse free-survival, with a p value of 0,15 and 0,2 respectively. CONCLUSIONS: There is not any advantage to determine c-erb-2 as a prognostic factor on overall survival either on relapse free-survival. Attending the homogenous characteristics between both groups with any statistical differences according age.en
dc.identifier.citationActa Med Port. 2004 Jul-Aug;17(4):271-6en
dc.identifier.urihttp://hdl.handle.net/10400.4/39
dc.language.isoporen
dc.subjectNeoplasias da Mamaen
dc.subjectTamoxifenoen
dc.subjectImunohistoquímicaen
dc.titleValor prognóstico da expressão por imuno-histoquímica do c-erb-2: em doentes sob terapêutica adjuvante com Tamoxifeno por carcinoma primário da mamaen
dc.title.alternativePrognostic value of c-erb-2 immunohistochemistry expression in patients with primary breast cancer and adjuvant treatment with tamoxifenen
dc.typejournal article
dspace.entity.typePublication
rcaap.rightsopenAccess
rcaap.typearticleen

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
RID9 Acta Med Port 271.pdf
Size:
127.45 KB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.8 KB
Format:
Item-specific license agreed upon to submission
Description: